Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Nasopharyngeal Carcinoma 4Triple Negative Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Cancer Patients 1Pancreatic Neoplasms 1Locally Advanced Rectal Cancer 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 14Paclitaxel 12pembrolizumab 9Fluorouracil 7Radiotherapy 6Irinotecan 5Esophagectomy 5tislelizumab 4Oxaliplatin 4Leucovorin 4Drug Therapy 4Carboplatin 4toripalimab 3Levoleucovorin 3Docetaxel 3Capecitabine 3camrelizumab 2Taxes 2Radiation 2Nivolumab 2Injections 2130-nm albumin-bound paclitaxel 2spartalizumab 1sintilimab 1palbociclib 1nimotuzumab 1nazartinib 1lenvatinib 1ivarmacitinib 1futibatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × camrelizumab × 90 days × Clear all
NCT06654297 2026-04-02

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

West China Hospital

Phase 1 Active not recruiting
6 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡